An additional predictive molecular target with multi-tumor approved agents are RET alterations, with potentially sensitizing mutations seen in approximately 70% of medullary thyroid cancers (MTC), fusions in <10% of other thyroid cancers and fusions in 1–2% of NSCLC [147,148,149]. This evidence concerns the gene RET and neoplasm.